Licensing
Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift
Actionable Insights Powered by AI
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift